- Home
- BON vs KPRX Comparison
BON vs KPRX Comparison
Compare BON & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BON
- KPRX
- Stock Information
- Founded
- BON 2006
- KPRX 1998
- Country
- BON China
- KPRX United States
- Employees
- BON N/A
- KPRX N/A
- Industry
- BON Medicinal Chemicals and Botanical Products
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- BON Health Care
- KPRX Health Care
- Exchange
- BON Nasdaq
- KPRX Nasdaq
- Market Cap
- BON 9.9M
- KPRX 11.0M
- IPO Year
- BON 2021
- KPRX N/A
- Fundamental
- Price
- BON $1.58
- KPRX $3.31
- Analyst Decision
- BON
- KPRX Strong Buy
- Analyst Count
- BON 0
- KPRX 1
- Target Price
- BON N/A
- KPRX $10.00
- AVG Volume (30 Days)
- BON 13.4K
- KPRX 47.3K
- Earning Date
- BON 11-29-2024
- KPRX 11-26-2024
- Dividend Yield
- BON N/A
- KPRX N/A
- EPS Growth
- BON N/A
- KPRX N/A
- EPS
- BON 2.19
- KPRX 1.69
- Revenue
- BON $25,555,939.00
- KPRX $16,020,000.00
- Revenue This Year
- BON $47.04
- KPRX N/A
- Revenue Next Year
- BON $77.63
- KPRX N/A
- P/E Ratio
- BON $0.67
- KPRX $1.96
- Revenue Growth
- BON N/A
- KPRX N/A
- 52 Week Low
- BON $1.23
- KPRX $3.00
- 52 Week High
- BON $6.99
- KPRX $8.98
- Technical
- Relative Strength Index (RSI)
- BON 57.03
- KPRX 43.88
- Support Level
- BON $1.35
- KPRX $3.20
- Resistance Level
- BON $1.56
- KPRX $3.49
- Average True Range (ATR)
- BON 0.11
- KPRX 0.19
- MACD
- BON 0.02
- KPRX -0.03
- Stochastic Oscillator
- BON 82.41
- KPRX 23.44
About BON Bon Natural Life Limited
Bon Natural Life Ltd is engaged in the manufacturing of personal care ingredients, such as plants extracted fragrance compounds to perfume and fragrance manufacturers, natural health supplements such as powder drinks and bioactive food ingredient products mostly used as food additives and nutritional supplements. The company has its geographic presence in PRC and in Overseas.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.